Preclinical pharmacology and antitumour activity of the novel sequence selective DNA minor-groove cross-linking agent DSB-120

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 5, 1996, Pages 431-438

  Walton, M I ^a   Goddard, P ^a   Kelland, L R ^a   Thurston, D E ^b   Harrap, K R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Cytotoxicity; DNA cross linking; DSB 120; Pharmokinetics; Sequence selectivity

Indexed keywords

CISPLATIN; DOXORUBICIN; DSB 120; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; COLONIC NEOPLASMS; DOXORUBICIN; DRUG STABILITY; FEMALE; LEUKEMIA L1210; MALE; MICE; MICE, INBRED BALB C; PLASMACYTOMA; PROTEIN BINDING; TUMOR CELLS, CULTURED;

EID: 0029773393     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050507     Document Type: Article

References (23)

1. Bose DS, Jones GB, Thurston DE (1992) New approaches to pyrrolo [2, 1-c] [1, 4] benzodiazepines: synthesis, DNA-binding and cytotoxicity of DC-81. Tetrahedron 48:751
2. Bose DS, Thompson AS, Ching J, Hartley JA, Berardini MD, Jenkins TC, Neidle S, Hurley LH, Thurston DE (1992) Rational design of a highly efficient irreversible DNA interstrand crosslinking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc 114:4939
3. Bose DS, Thompson AS, Smellie M, Beradini MD, Hartley JA, Jenkins TC, Neidle S, Thurston DE (1992) Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. J Chem Soc [D] 14:1518
4. D'lncalci M, Broggini M, Hartley JA (1992) Sequence and gene-specific drugs. In: Workman P (ed) New approaches in cancer pharmacology: drug design and development. Springer. New York Berlin Heidelberg, pp 5-11
5. Dvorchik BH, Vesell ES (1978) Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Cancer Ther 23:617
6. Goddard PM, Valenti MR, Harrap KR (1991) The role of murine tumour models and their acquired platinum-resistant counterparts in the evolution of novel platinum antitumour agents: a cautionary note. Ann Oncol 2:535
7. Honess DJ, Bleehen NM (1982) Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: lack of therapeutic gain. Br J Cancer 46:236
8. Jenkins TC, Hurley LH, Neidle S, Thurston DE (1994) Structure of a covalent DNA minor-groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem 37:4529
9. Jennrich RI, Sampson PF (1968) Application of a stepwise regression to non-linear estimation. Technometrics 10:63
10. Jones GB, Davey CL, Jenkins TC, Kamal A, Kneale GG, Neidle S. Webster GD, Thurston DE (1990) The non-covalent interaction of pyrrolo[2, 1-c] [1, 4]benzodiazepine-5, 11-diones with DNA. Anticancer Drug Des 5:249
11. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Vallenti M, Murrer B, Harrap KR (1993) Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum compound. Cancer Res 53:2581
12. Lee FYF, Workman P (1983) Modification of CCNU pharmacokinetics by misonidazole a major mechanism of chemosensitisation in mice. Br J Cancer 47:659
13. Lee FYF, Coe P, Workman P (1986) Pharmacokinetic basis for the comparative antitumour activity and toxicity of chloram-bucil, phenylacetic acid mustard and ββ-difluorochlorambucil (CB 7103) in mice. Cancer Chemother Pharmacol 17:21
14. Moutzouris JA, Wang JJ, Thurston DE, Hurley LH (1994) Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-tomaymycin adduct: an example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin. J Med Chem 37:3132
15. Neidle S, Puvvada MS, Thurston DE (1994) The relevance of drug-DNA sequence-specificity to antitumour activity. Eur J Cancer 30:567
16. Potter M, Robertson CL (1960) Development of plasma-cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin-oil adjuvant, heat-killed staphylococcus mixtures. J Natl Cancer Inst 25:847
17. Puvvada MS, Hartley JA, Jenkins TC, Thurston DE (1993) A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) anti-tumour antibiotics based on the inhibition of restriction endonuclease BamH1. Nucleic Acids Res 21:3671
18. Shaw LM, Bonner HS, Brown DQ (1994) Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 22:895
19. Smellie M, Kelland LR, Thurston DE, Souhami RL, Hartley JA (1994) Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. Br J Cancer 70:48
20. Thurston DE (1993) Advances in the study of pyrrolo[2, 1-c] [1, 4]benzodiazepine (PBD) antitumour antibiotics. In: Neidle S, Waring M (eds) Molecular aspects of anticancer drug-DNA interactions. Macmillan, London, pp 54-88
21. Thurston DE, Morris SJ, Nevell TG (1990) Evaluation of the electrophilicity of DNA-binding pyrrolo[2, 1-c][1, 4]benzodiazepines by HPLC. J Antibiot (Tokyo) 43:1286
22. Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence, Chicago. Illinois
23. Walton MI, Workman P (1993) Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cytotoxin tirapazamine (WIN 59075; SR 4233: NSC 130181) in mice. J Pharmacol Exp Ther 265:938